Alvarez & Marsal Managing Director Mark Freitas was featured among Top 25 Life Sciences Consultants and Leaders of 2024
The Consulting Report is pleased to announce The Top 25 Life Sciences Consultants and Leaders of 2024. The life sciences industry has undergone significant transformation in recent years, fueled by scientific breakthroughs, technological innovation, and the global impact of the COVID-19 pandemic. While these shifts have ushered in new opportunities for patient care, drug development, and medical innovation, they have also presented complex challenges. Life sciences organizations now face increased pressure to optimize pricing, navigate unpredictable market access, adapt to changing consumer behavior, and enhance operational efficiency.
Mark Freitas specializes in helping businesses reach their full potential by developing successful strategies that maximize growth while avoiding operational challenges. His expertise spans corporate finance and operations, strategic planning, board governance, mergers and acquisitions activity, risk management, and compliance.
Read the Full Article Here
LS: Next Growth Curve
April 22, 2026
Developed markets are facing structural headwinds, such as affordability constraints, pricing reform, as demographic saturation and slower volume growth are limiting expansion and resulting a moderating growth rate. In contrast, emerging markets are entering a phase of healthcare formalization and access expansion driven by rising chronic disease burden and government prioritization of pharmaceuticals
Q4 | 2025 NAVIGATING DEALFLOW: EUROPEAN SOFTWARE QUARTERLY
March 19, 2026
After years of rising growth multiples, Europe’s software market is repricing. Our first Navigating Dealflow: European Software Quarterly brings a clear view of how this reset is changing M&A, where valuations are landing, and which segments are holding up.
CDMO platforms will be the central arena for MedTech M&A in 2026
February 19, 2026
The MedTech manufacturing landscape is entering a pivotal phase.
Navigating Global Pharma Policy
January 26, 2026
As the U.S. considers imposing tariffs on European pharmaceutical imports, the ripple effects could be felt across the global healthcare landscape. For an industry already grappling with rising R&D costs and competitive pressures, these tariffs threaten to erode profit margins and disrupt finely tuned supply chains.
